Transferring care to enhance access to early-phase cancer clinical trials: Protocol to evaluate a novel program

IF 1.4 Q4 MEDICINE, RESEARCH & EXPERIMENTAL
Chika Nwachukwu , Sukh Makhnoon , Marieshia Person , Meera Muthukrishnan , Syed Kazmi , Larry D. Anderson , Gurbakhash Kaur , Kandice A. Kapinos , Erin L. Williams , Oluwatomilade Fatunde , Navid Sadeghi , Fabian Robles , Alice Basey , Thomas Hulsey , Sandi L. Pruitt , David E. Gerber
{"title":"Transferring care to enhance access to early-phase cancer clinical trials: Protocol to evaluate a novel program","authors":"Chika Nwachukwu ,&nbsp;Sukh Makhnoon ,&nbsp;Marieshia Person ,&nbsp;Meera Muthukrishnan ,&nbsp;Syed Kazmi ,&nbsp;Larry D. Anderson ,&nbsp;Gurbakhash Kaur ,&nbsp;Kandice A. Kapinos ,&nbsp;Erin L. Williams ,&nbsp;Oluwatomilade Fatunde ,&nbsp;Navid Sadeghi ,&nbsp;Fabian Robles ,&nbsp;Alice Basey ,&nbsp;Thomas Hulsey ,&nbsp;Sandi L. Pruitt ,&nbsp;David E. Gerber","doi":"10.1016/j.conctc.2024.101292","DOIUrl":null,"url":null,"abstract":"<div><p>Involving diverse populations in early-phase (phase I and II) cancer clinical trials is critical to informed therapeutic development. However, given the growing costs and complexities of early-phase trials, trial activation and enrollment barriers may be greatest for these studies at healthcare facilities that provide care to the most diverse patient groups, including those in historically underserved communities (e.g., safety-net healthcare systems). To promote diverse and equitable access to early-phase cancer clinical trials, we are implementing a novel program for the transfer of care to enhance access to early-phase cancer clinical trials. We will then perform a mixed-methods study to determine perceptions and impact of the program. Specifically, we will screen, recruit, and enroll diverse patients from an urban, integrated safety-net healthcare system to open and active early-phase clinical trials being conducted in a university-based cancer center. To evaluate this novel program, we will: (1) determine program impact and efficiency; and (2) determine stakeholder experience with and perceptions of the program. To achieve these goals, we will conduct preliminary cost analyses of the program. We will also conduct surveys and interviews with patients and caregivers to elucidate program impact, challenges, and areas for improvement. We hypothesize that broadening access to early-phase cancer trials conducted at experienced centers may improve equity and diversity. In turn, such efforts may enhance the efficiency and generalizability of cancer clinical research.</p></div>","PeriodicalId":37937,"journal":{"name":"Contemporary Clinical Trials Communications","volume":"39 ","pages":"Article 101292"},"PeriodicalIF":1.4000,"publicationDate":"2024-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2451865424000395/pdfft?md5=3cc23e5e9c345fabd1afdaea296dc5b6&pid=1-s2.0-S2451865424000395-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Contemporary Clinical Trials Communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2451865424000395","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Involving diverse populations in early-phase (phase I and II) cancer clinical trials is critical to informed therapeutic development. However, given the growing costs and complexities of early-phase trials, trial activation and enrollment barriers may be greatest for these studies at healthcare facilities that provide care to the most diverse patient groups, including those in historically underserved communities (e.g., safety-net healthcare systems). To promote diverse and equitable access to early-phase cancer clinical trials, we are implementing a novel program for the transfer of care to enhance access to early-phase cancer clinical trials. We will then perform a mixed-methods study to determine perceptions and impact of the program. Specifically, we will screen, recruit, and enroll diverse patients from an urban, integrated safety-net healthcare system to open and active early-phase clinical trials being conducted in a university-based cancer center. To evaluate this novel program, we will: (1) determine program impact and efficiency; and (2) determine stakeholder experience with and perceptions of the program. To achieve these goals, we will conduct preliminary cost analyses of the program. We will also conduct surveys and interviews with patients and caregivers to elucidate program impact, challenges, and areas for improvement. We hypothesize that broadening access to early-phase cancer trials conducted at experienced centers may improve equity and diversity. In turn, such efforts may enhance the efficiency and generalizability of cancer clinical research.

通过转诊增加早期癌症临床试验的机会:一项新计划的评估方案
让不同人群参与早期(I 期和 II 期)癌症临床试验对于开发知情疗法至关重要。然而,由于早期试验的成本和复杂性不断增加,在为最多样化的患者群体提供医疗服务的医疗机构中,包括那些历史上服务不足的社区(如安全网医疗系统),这些研究的试验启动和注册障碍可能最大。为了促进多样化和公平地参与早期癌症临床试验,我们正在实施一项新颖的护理转移计划,以提高早期癌症临床试验的可及性。然后,我们将开展一项混合方法研究,以确定对该计划的看法和影响。具体来说,我们将筛选、招募城市综合安全网医疗系统中的不同患者,并将其纳入大学癌症中心正在进行的开放和活跃的早期临床试验。为了评估这项新计划,我们将(1) 确定计划的影响和效率;(2) 确定利益相关者对计划的体验和看法。为了实现这些目标,我们将对该计划进行初步的成本分析。我们还将对患者和护理人员进行调查和访谈,以阐明计划的影响、挑战和需要改进的地方。我们假设,扩大在经验丰富的中心进行早期癌症试验的机会可以提高公平性和多样性。反过来,这些努力也会提高癌症临床研究的效率和普及性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Contemporary Clinical Trials Communications
Contemporary Clinical Trials Communications Pharmacology, Toxicology and Pharmaceutics-Pharmacology
CiteScore
2.70
自引率
6.70%
发文量
146
审稿时长
20 weeks
期刊介绍: Contemporary Clinical Trials Communications is an international peer reviewed open access journal that publishes articles pertaining to all aspects of clinical trials, including, but not limited to, design, conduct, analysis, regulation and ethics. Manuscripts submitted should appeal to a readership drawn from a wide range of disciplines including medicine, life science, pharmaceutical science, biostatistics, epidemiology, computer science, management science, behavioral science, and bioethics. Contemporary Clinical Trials Communications is unique in that it is outside the confines of disease specifications, and it strives to increase the transparency of medical research and reduce publication bias by publishing scientifically valid original research findings irrespective of their perceived importance, significance or impact. Both randomized and non-randomized trials are within the scope of the Journal. Some common topics include trial design rationale and methods, operational methodologies and challenges, and positive and negative trial results. In addition to original research, the Journal also welcomes other types of communications including, but are not limited to, methodology reviews, perspectives and discussions. Through timely dissemination of advances in clinical trials, the goal of Contemporary Clinical Trials Communications is to serve as a platform to enhance the communication and collaboration within the global clinical trials community that ultimately advances this field of research for the benefit of patients.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信